IDO1 and non-small cell lung carcinoma: The rs10108662 SNP in indoleamine-2,3-dioxygenase 1 (IDO1) was associated with a higher risk of death, potentially affecting NSCLC patient outcomes by modulating the expression of IDO and T cell cytotoxicity.